Lucid Diagnostics (LUCD) Stock Forecast, Price Target & Predictions
LUCD Stock Forecast
Lucid Diagnostics stock forecast is as follows: an average price target of $2.67 (represents a 167.27% upside from LUCD’s last price of $1.00) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LUCD Price Target
The average price target for Lucid Diagnostics (LUCD) is $2.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $2.50. This represents a potential 167.27% upside from LUCD's last price of $1.00.
LUCD Analyst Ratings
According to 3 Wall Street analysts, Lucid Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for LUCD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Lucid Diagnostics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Mike Matson | Needham | - | - | 216.46% | 150.25% |
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | - | - | 215.79% | 200.30% |
| Apr 08, 2024 | Mark Massaro | BTIG | - | - | 169.48% | 150.25% |
| Nov 18, 2022 | BTIG | - | - | 83.25% | 250.35% | |
| Nov 15, 2022 | Needham | - | - | 36.56% | 210.31% |
The latest Lucid Diagnostics stock forecast, released on Nov 13, 2024 by Mike Matson from Needham, set a price target of $2.50, which represents a 216.46% increase from the stock price at the time of the forecast ($0.79), and a 150.25% increase from LUCD last price ($1.00).
Lucid Diagnostics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $2.50 | $2.50 | $2.67 |
| Last Closing Price | $1.00 | $1.00 | $1.00 |
| Upside/Downside | 150.25% | 150.25% | 167.27% |
In the current month, the average price target of Lucid Diagnostics stock is $2.50, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 150.25% increase as opposed to Lucid Diagnostics's last price of $1.00. This month's average price target is down 0.00% compared to last quarter, and down -6.37% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | BTIG | Buy | Buy | Hold |
| Apr 08, 2024 | BTIG | Buy | Buy | Hold |
| Nov 18, 2022 | BTIG | Buy | Buy | Hold |
| Nov 15, 2022 | Needham | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | Sell | Downgrade |
Lucid Diagnostics's last stock rating was published by BTIG on Oct 14, 2024. The company gave LUCD a "Buy" rating, the same as its previous rate.
Lucid Diagnostics Financial Forecast
Lucid Diagnostics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.04M | $783.00K | $159.00M | $446.00K | $112.00K | $76.00K | - | $189.00K | $300.00K | $200.00K |
| Avg Forecast | $11.52M | $18.17M | $8.67M | $6.57M | $3.78M | $2.80M | $2.31M | $1.86M | $1.39M | $1.14M | $1.22M | $1.05M | $1.04M | $799.67K | $620.00K | $238.78K | $341.74K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| High Forecast | $13.21M | $20.83M | $9.94M | $7.53M | $4.34M | $3.21M | $2.65M | $2.14M | $1.59M | $1.30M | $1.22M | $1.05M | $1.29M | $803.01K | $710.85K | $273.77K | $391.81K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| Low Forecast | $10.65M | $16.80M | $8.02M | $6.07M | $3.50M | $2.59M | $2.14M | $1.72M | $1.29M | $1.05M | $1.22M | $1.05M | $891.43K | $796.34K | $573.20K | $220.76K | $315.95K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.98% | 256.45% | 1.87% | 0.33% | 0.18% | - | 0.41% | 0.77% | 3.67% |
Lucid Diagnostics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.05M, with a low forecast of $1.05M, and a high forecast of $1.05M. LUCD's average Quarter revenue forecast represents a 0.77% increase compared to the company's last Quarter revenue of $1.04M (Dec 23).
Lucid Diagnostics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-10.82M | $-13.41M | $-11.58B | $-15.60M | $-14.31M | $-13.76M | $-13.92M | $-12.07M | $-11.24M | $-6.51M |
| Avg Forecast | $-2.30M | $-3.63M | $-1.73M | $-1.31M | $-756.70K | $-560.45K | $-462.64K | $-372.55K | $-278.20K | $-227.30K | $-244.53K | $-209.60K | $-208.00K | $-159.93K | $-124.00K | $-47.76K | $-68.35K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-3.82B |
| High Forecast | $-2.13M | $-3.36M | $-1.60M | $-1.21M | $-699.59K | $-518.15K | $-427.72K | $-344.43K | $-257.20K | $-210.14K | $-244.49K | $-209.20K | $-178.28K | $-159.27K | $-114.64K | $-44.15K | $-63.19K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-3.05B |
| Low Forecast | $-2.64M | $-4.17M | $-1.99M | $-1.51M | $-867.58K | $-642.57K | $-530.42K | $-427.13K | $-318.96K | $-260.61K | $-244.56K | $-210.00K | $-257.52K | $-160.60K | $-142.17K | $-54.75K | $-78.36K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-4.58B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 52.04% | 83.83% | 93420.11% | 326.71% | 209.42% | 159.45% | 110.41% | 130.42% | 143.78% | 0.00% |
undefined analysts predict LUCD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lucid Diagnostics's previous annual EBITDA (undefined) of $NaN.
Lucid Diagnostics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-10.83M | $-14.21M | $-11.38B | $-1.98B | $-14.76M | $-14.35M | $-14.62M | $-12.44M | $-11.37M | $-7.40M |
| Avg Forecast | - | - | - | - | $-8.69M | $-8.06M | $-9.32M | $-9.57M | $-8.87M | $-10.38M | $-10.07M | $-12.09M | $-11.59M | $-11.96M | $-14.23M | $-16.38M | $-16.62M | $-16.93M | $-16.05M | $-12.51M | $-12.41M | $-3.59B |
| High Forecast | - | - | - | - | $-7.84M | $-7.27M | $-8.40M | $-8.63M | $-8.00M | $-9.36M | $-9.09M | $-10.90M | $-8.47M | $-10.79M | $-12.83M | $-14.77M | $-14.99M | $-16.93M | $-16.05M | $-12.51M | $-12.41M | $-2.87B |
| Low Forecast | - | - | - | - | $-10.34M | $-9.60M | $-11.09M | $-11.39M | $-10.55M | $-12.35M | $-11.99M | $-14.39M | $-13.37M | $-14.24M | $-16.94M | $-19.50M | $-19.79M | $-16.93M | $-16.05M | $-12.51M | $-12.41M | $-4.30B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.19% | 799.75% | 120.83% | 0.89% | 0.85% | 0.91% | 0.99% | 0.92% | 0.00% |
Lucid Diagnostics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LUCD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lucid Diagnostics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.49M | $8.16M | $7.86B | $10.64M | $10.47M | $9.59M | $11.18M | $9.04M | $7.62M | $4.38M |
| Avg Forecast | $364.98M | $575.62M | $274.74M | $208.01M | $119.85M | $88.77M | $73.27M | $59.00M | $44.06M | $36.00M | $38.73M | $33.20M | $32.94M | $25.33M | $19.64M | $7.56M | $10.83M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| High Forecast | $418.45M | $659.96M | $314.99M | $238.49M | $137.41M | $101.77M | $84.01M | $67.65M | $50.52M | $41.28M | $38.73M | $33.26M | $40.79M | $25.44M | $22.52M | $8.67M | $12.41M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| Low Forecast | $337.43M | $532.17M | $254.00M | $192.31M | $110.80M | $82.07M | $67.74M | $54.55M | $40.74M | $33.28M | $38.72M | $33.13M | $28.24M | $25.23M | $18.16M | $6.99M | $10.01M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.26% | 0.32% | 400.32% | 1.41% | 0.97% | 0.70% | 0.56% | 0.62% | 0.62% | 2.54% |
Lucid Diagnostics's average Quarter SG&A projection for Mar 24 is $33.20M, based on 3 Wall Street analysts, with a range of $33.13M to $33.26M. The forecast indicates a 291.06% rise compared to LUCD last annual SG&A of $8.49M (Dec 23).
Lucid Diagnostics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.34 | $-272.05 | $-48.31 | $-0.41 | $-0.39 | $-0.41 | $-0.35 | $-0.31 | $-0.20 |
| Avg Forecast | - | - | - | - | $-0.17 | $-0.16 | $-0.18 | $-0.19 | $-0.18 | $-0.21 | $-0.20 | $-0.24 | $-0.23 | $-0.24 | $-0.28 | $-0.33 | $-0.33 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| High Forecast | - | - | - | - | $-0.16 | $-0.14 | $-0.17 | $-0.17 | $-0.16 | $-0.19 | $-0.18 | $-0.22 | $-0.17 | $-0.21 | $-0.25 | $-0.29 | $-0.30 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| Low Forecast | - | - | - | - | $-0.21 | $-0.19 | $-0.22 | $-0.23 | $-0.21 | $-0.25 | $-0.24 | $-0.29 | $-0.27 | $-0.28 | $-0.34 | $-0.39 | $-0.39 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.13% | 1.43% | 963.01% | 148.56% | 1.24% | 1.11% | 1.23% | 1.35% | 1.20% | 0.70% |
According to undefined Wall Street analysts, Lucid Diagnostics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LUCD previous annual EPS of $NaN (undefined).
Lucid Diagnostics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUCD | Lucid Diagnostics | - | - | 167.00% | Buy |
| XAIR | Beyond Air | - | - | 85.19% | Buy |
| LUNG | Pulmonx | - | - | 75.70% | Buy |
| KIDS | OrthoPediatrics | - | - | 50.34% | Buy |
| LIVN | LivaNova | - | - | 37.37% | Buy |
| NARI | Inari Medical | - | - | 33.13% | Buy |
| NPCE | NeuroPace | - | - | 32.78% | Buy |
| OFIX | Orthofix Medical | - | - | 26.92% | |
| FNA | Paragon 28 | - | - | 14.54% | Buy |
| IRMD | IRadimed | - | - | 12.72% | Buy |
| CVRX | CVRx | - | - | 9.97% | Buy |
| CLPT | ClearPoint Neuro | - | - | 1.35% | Buy |
| SRDX | Surmodics | - | - | 0.43% | Buy |
| ITGR | Integer | - | - | -0.08% | Buy |